Congo Ebola deaths pass 3,000 as Bundibugyo strain spreads through six provinces

The Democratic Republic of Congo's National Institute of Public Health put the Ebola death toll at 3,007 on Wednesday, with 6,186 confirmed cases. The case fatality rate stands at 48.6 percent. Another 1,409 people have recovered. About 830 patients remain in isolation or treatment centres. The outbreak is now the largest and deadliest in Congo's own record, and the second largest ever recorded, behind the 2014-2016 West Africa epidemic that killed more than 11,000 people across Guinea, Liberia and Sierra Leone.

The strain is Bundibugyo, first identified in Uganda in 2007. It has no approved vaccine and no licensed specific treatment. That fact separates this epidemic from the 2018-2020 North Kivu outbreak, which was Zaire ebolavirus and could use the Ervebo vaccine. Congo's previous worst outbreak in 2018-2020 killed nearly 2,300 people from about 3,500 reported cases.

Where the virus is moving

Authorities formally declared the outbreak in Ituri province on 15 May. Some health officials say transmission may have started as early as January. The virus has since reached 60 health zones in six provinces: Ituri, North Kivu, Haut-Uele, Tshopo, South Kivu and Bas-Uele. Ituri still accounts for 81.9 percent of confirmed cases. North Kivu is recording a higher fatality rate than the national average. Two new health zones there were added last week.

The World Health Organization estimates that about 60 percent of deaths occur outside treatment centres. Patients die at home or on the road before they are logged. Africa CDC has said the true caseload could be three times the official count because contact tracing remains thin. More than 40 health workers have died. Treatment centres and ambulances have been attacked in areas where armed groups operate and state presence is weak.

What responders can actually use

Ervebo is licensed against the Zaire strain. WHO has issued updated emergency guidance on whether it can be used here. Africa CDC said 70,000 doses are being made available and more than 16,000 have already arrived. Early laboratory and animal work suggests some cross-protection. Africa CDC said it has no evidence that Bundibugyo has mutated. Clinical trials of two antiviral candidates have been running since early July. Oxford and the International AIDS Vaccine Initiative have Bundibugyo-specific vaccine candidates in development. None of those products is a licensed tool on the ground today.

School has resumed in the middle of the outbreak, which raises the chance of classroom transmission in zones that still lack isolation beds. Young children are dying at higher rates than adults.

Why this one outran the last

The 2018-2020 epidemic was fought with a licensed vaccine, a large international deployment and a clearer map of contacts. This one started in a remote corner of Ituri, moved through conflict territory, and involves a virus for which the stockpile was not built. UN officials say the virus is now spreading faster than the response. That sentence is the operational fact. The next threshold that public-health agencies are watching is whether weekly incidence keeps climbing after the 3,000-death mark, or whether isolation capacity and the experimental shots can flatten it before the caseload approaches the West Africa totals.